Allogene Therapeutics, Inc. (ALLO)

Market Cap	594.82M +30.1%
Revenue (ttm)	n/a
Net Income	-190.89M
EPS	-0.87
Shares Out	243.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,688,885
Open	2.140
Previous Close	2.070
Day's Range	2.130 - 2.600
52-Week Range	0.862 - 2.800
Beta	0.50
Analysts	Buy
Price Target	8.40 (+244.26%)
Earnings Date	Mar 12, 2026

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO
• Website: https://allogene.com

Analyst Summary

According to 11 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price target is $8.4, which is an increase of 244.26% from the latest price.

Price Target

$8.4

(244.26% upside)

Analyst Consensus: Buy